Medicinal Chemistry Research, H. Lundbeck A/S, Valby, Denmark.
Bioorg Med Chem Lett. 2010 Sep 1;20(17):5241-4. doi: 10.1016/j.bmcl.2010.06.138. Epub 2010 Jul 24.
Herein we describe the discovery of a series of novel adenosine A(2A) receptor antagonists. A successful hit-to-lead optimization of an HTS hit led to replacement of a metabolically labile ester moiety with a heteroaromatic group. A compound from the series, (cyclopropanecarboxylic acid [5-(5-methyl-[1,2,4]oxadiazol-3-yl)-4-phenyl-thiazol-2-yl]-amide, compound 13), was shown to be effective in reversing haloperidol-induced hypolocomotion, a model of motor dysfunction in Parkinson's Disease.
在此,我们描述了一系列新型的腺苷 A(2A)受体拮抗剂的发现。通过对高通量筛选(HTS)命中化合物的成功的从头优化,我们将代谢不稳定的酯部分替换为杂芳基。该系列化合物中的一种(环丙烷羧酸[5-(5-甲基-[1,2,4]恶二唑-3-基)-4-苯基-噻唑-2-基]-酰胺,化合物 13)被证明能有效逆转氟哌啶醇诱导的运动不能,这是帕金森病运动功能障碍的一种模型。